BioCentury
ARTICLE | Clinical News

TB-403: Phase I/IIa started

May 9, 2016 7:00 AM UTC

Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages 6 months to 18 years old. The dose-escalation Phase I portion will test 20-175 mg/kg TB-403. The Phase IIa portion will further assess the safety of the MTD. ...